448 related articles for article (PubMed ID: 18220478)
1. Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences.
Legendre C; Pascual M
Clin Infect Dis; 2008 Mar; 46(5):732-40. PubMed ID: 18220478
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies.
Singh N
J Clin Virol; 2006 Apr; 35(4):474-7. PubMed ID: 16406798
[TBL] [Abstract][Full Text] [Related]
3. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients.
Singh N
Clin Infect Dis; 2001 Mar; 32(5):742-51. PubMed ID: 11229841
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation.
Fisher RA
Transpl Infect Dis; 2009 Jun; 11(3):195-202. PubMed ID: 19228345
[TBL] [Abstract][Full Text] [Related]
5. Benefits of cytomegalovirus prophylaxis in solid organ transplantation.
Pescovitz MD
Transplantation; 2006 Jul; 82(2 Suppl):S4-8. PubMed ID: 16858270
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G
J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105
[TBL] [Abstract][Full Text] [Related]
7. The case for cytomegalovirus prophylaxis in solid organ transplantation.
Snydman DR
Rev Med Virol; 2006; 16(5):289-95. PubMed ID: 16888821
[TBL] [Abstract][Full Text] [Related]
8. Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy.
Alberú J; Morales-Buenrostro LE; Correa-Rotter R; Muñoz-Trejo T; Zúñiga-Varga J; Cuéllar-González JV; Mayorga-Madrigal H; Vanegas-Carrero R; Aranda F; Rodríguez-Romo R; Herrera-Garcia C; González-Michaca L; Sierra-Madero JG
Rev Invest Clin; 2008; 60(5):365-74. PubMed ID: 19227433
[TBL] [Abstract][Full Text] [Related]
9. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.
Strippoli GF; Hodson EM; Jones C; Craig JC
Transplantation; 2006 Jan; 81(2):139-45. PubMed ID: 16436954
[TBL] [Abstract][Full Text] [Related]
10. Prevention of cytomegalovirus disease in recipients of solid-organ transplants.
Paya CV
Clin Infect Dis; 2001 Feb; 32(4):596-603. PubMed ID: 11181123
[TBL] [Abstract][Full Text] [Related]
11. Defining the risks for cytomegalovirus infection and disease after solid organ transplantation.
Stratta RJ; Pietrangeli C; Baillie GM
Pharmacotherapy; 2010 Feb; 30(2):144-57. PubMed ID: 20099989
[TBL] [Abstract][Full Text] [Related]
12. The economic value of valacyclovir prophylaxis in transplantation.
Squifflet JP; Legendre C
J Infect Dis; 2002 Oct; 186 Suppl 1():S116-22. PubMed ID: 12353196
[TBL] [Abstract][Full Text] [Related]
13. [Prevention of cytomegalovirus disease in lung transplantation].
Gavaldà J; Monforte V; Len Ó
Enferm Infecc Microbiol Clin; 2011 Dec; 29 Suppl 6():46-51. PubMed ID: 22541923
[TBL] [Abstract][Full Text] [Related]
14. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis.
Bonaros N; Mayer B; Schachner T; Laufer G; Kocher A
Clin Transplant; 2008; 22(1):89-97. PubMed ID: 18217909
[TBL] [Abstract][Full Text] [Related]
15. The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients.
Roman A; Manito N; Campistol JM; Cuervas-Mons V; Almenar L; Arias M; Casafont F; del Castillo D; Crespo-Leiro MG; Delgado JF; Herrero JI; Jara P; Morales JM; Navarro M; Oppenheimer F; Prieto M; Pulpón LA; Rimola A; Serón D; Ussetti P;
Transplant Rev (Orlando); 2014 Apr; 28(2):84-91. PubMed ID: 24602805
[TBL] [Abstract][Full Text] [Related]
16. Indirect effects of CMV in the solid organ transplant patient.
Paya CV
Transpl Infect Dis; 1999; 1 Suppl 1():8-12. PubMed ID: 11565588
[TBL] [Abstract][Full Text] [Related]
17. Management of cytomegalovirus infection and disease after solid-organ transplantation.
van der Bij W; Speich R
Clin Infect Dis; 2001 Jul; 33 Suppl 1():S32-7. PubMed ID: 11389520
[TBL] [Abstract][Full Text] [Related]
18. Strategies for prevention of cytomegalovirus infection in renal transplant patients.
Valenzuela M; Ortiz AM; Troncoso P; Vilches S
Transplant Proc; 2009; 41(6):2673-5. PubMed ID: 19715999
[TBL] [Abstract][Full Text] [Related]
19. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies.
Small LN; Lau J; Snydman DR
Clin Infect Dis; 2006 Oct; 43(7):869-80. PubMed ID: 16941368
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis and treatment of cytomegalovirus disease in recipients of solid organ transplants: current approach and future challenges.
Puius YA; Snydman DR
Curr Opin Infect Dis; 2007 Aug; 20(4):419-24. PubMed ID: 17609603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
